Bernard C. Rudnick
Bernard C. Rudnick is founder and Managing Partner of CapGenic Advisors, LLC, Chief Business Officer of NovoBioPharma and a member of several angel groups. Mr. Rudnick’s entrepreneurial career includes a number of startups, three of which grew to over $60 million in revenue before exiting. He is a founder of one of the nation’s leading entrepreneurial programs (MADV) at the Fox School of Business, a director of Otosound, director and CFO of Immunomic Therapeutics, and has held a number of other board positions – both commercial and not-for-profit – throughout his career. With 36 years of experience in executive-level strategy, finance, and management, Mr. Rudnick has senior merger, acquisition, capital formation and licensing leadership experience with companies ranging from start-up to Fortune 50. Mr. Rudnick has substantial experience investing and guiding investments in entrepreneurial companies, he has led capital formation and merger transactions totaling in the billions. Mr. Rudnick currently advises companies in the clinical software, therapeutic, medical device, and in the cell line engineering areas. His advisory clients have included Mitsui (Mitrix), DuPont (Agri-chemical), McKesson Bioservices (now TMO), Kika Clinical Solutions (now MRGE) as well as a number of early stage life sciences companies. Angel group affiliations include Minority Angel Investment Network, a founder of Mid-Atlantic Bio Angels www.bioangels.net and Keiretsu Mid-Atlantic. Not-for-profit board affiliations include Penn State Medical School and Temple University technology commercialization boards, and advisory to UPstart program at the University of Pennsylvania.
George Mulling has over 25 years of global sales and business development management
experience. He has held positions as VP Sales, Marketing and Business Development
with companies such as Bertelsmann, RR Donnelley/Modus Media International and Mitrix.
His primary industry experience includes supply chain services, logistics, technology,
manufacturing and customer relationship management. Mulling has taken businesses
from start-up to over $100 million globally and built complete sales and marketing
organizations in North America, Europe and Asia. He has managed new business development
for all these companies, combining the identification of viable markets and regions,
the creation of a compelling product and service offer and the delivery of revenue.
In addition to direct sales, Mulling has developed channel strategy and created
strategic and channel sales partnerships worldwide. His technology experience has
been with ecommerce as well as supply chain management technology, helping companies
to optimize their buy and sell side execution. Mulling has a BS in Business from
Virginia Tech and has done additional post-graduate business studies at both UCLA
and the University of Southern California. He has conducted numerous sales training
sessions with a focus on the practical aspects of managing the total sales process.
Dr. Ira Wallace
Managing Partner, Life Science
Dr. Wallace has over 20 years’ experience working with biotech, medical device, pharmaceutical and healthcare IT companies both as an entrepreneur and as a consultant. He has extensive experience in M&A, partnerships, business strategy and capital formation for mid-stage and early-stage companies. Ira is an active angel investor and currently serves as Regional Vice-President of Keiretsu Forum Mid-Atlantic and is on the steering committee of Mid-Atlantic Bio Angels. Dr. Wallace was the founding CEO if EyeIC, Inc and currently serves on the board of directors. He holds a BA from the University of Pennsylvania, an MD from Drexel University and an MBA from Columbia Business School of Columbia University in NYC.
Dr. Holly G. Atkinson
Venture Partner, Life Science
Dr. Atkinson joined CapGenic in the fall of 2002 after 22 years in the field of
medical information and medical education. She is the senior on-air Medical Correspondent
and Chief medical Editor of HealthiNation, the leading digital consumer health video
network, and the editor of HealthNews, the consumer health newsletter launched by
the Massachusetts Medical Society and now published by Belvoir Media Inc. In addition,
Dr. Atkinson is an Assistant Professor in the Department of Public Health at the
Weill Cornell Medical College. Dr. Atkinson was a founder as well as President and
CEO of Reuters Health Information, Inc., a whole owned subsidiary of Reuters PLC.
Within 3 years of taking the helm, she led the medical news company to profitability
and international recognition. Prior to joining Reuters, Atkinson was at Lifetime
Medical Television for 10 years where she oversaw, as Senior Vice President of Programming,
all of the continuing medical education programs aired on the network. Her years
as a medical correspondent for the CBS Morning News and NBC’s Today show, as well
as her countless appearances as a keynote speaker, have made her widely known and
respected. She brings to CapGenic a unique blend of business experience, media savvy,
educational acumen, and medical expertise. Dr. Atkinson devotes considerable time
to a number of non-profit organizations and charities. She is Past President of
Physicians for Human Rights, an organization that shared in the Nobel Peace Prize
in 1997 for its effort to eradicate landmines. In 1995, Dr. Atkinson conducted a
medical mission to Bosnia where she documented the health effects of landmines on
the civilian population. She has also served on the boards of Legal Momentum, the
nation's oldest and largest women's civil rights organization; the American Heart
Association; and the Society for Women's Health Research. She has a MD from the
University of Rochester School of Medicine and Dentistry and a MS degree in journalism
from the Columbia University Graduate School of Journalism, and is a fellow of the
American College of Physicians.
Dr. Phillip Cox
Venture Partner, Life Science
D. Phillip Cox, PhD, formerly Chief Scientist at Noramco Inc, formerly a Johnson & Johnson company. He specializes in the chemical development and scale-up of small molecule APIs and is a certified Black Belt in Design Excellence with substantial experience, and multi-million dollar cost savings, in Lean and 6 sigma initiatives. He served as Director of the Chemistry Services Department for 6 years, was on the Senior Management Team for two years and was a member of the Noramco Board for a further two years. His most recent roles at Noramco were the management of outsourced R&D projects and the management of offensive and defensive aspects of Noramco’s intellectual property. He also initiated significant new business opportunities for Noramco. He has 6 granted patents, four other applications have been filed, and is co-author on 15 peer-reviewed publications in the opiate chemistry area.